MiNK Therapeutics Board Member Sells 1,500 Shares, Hinting at Possible Cautious Shift Ahead
Insider sales of MiNK Therapeutics’ shares hint at a cautious outlook, even as the company’s pediatric cell‑therapy partnership fuels upside potential.
3 minutes to read